deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT00719914

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks (IC TITAN)

IntraCoronary Treatment With Integrilin To Improve ANgiographic Outcomes (IC TITAN - TIMI 47) Trial

Sponsor: Brigham and Women's Hospital

Conditions ST-Elevation Myocardial Infarction
Interventions eptifibatide normal saline
Updated 10 times since 2017 Last updated: Jul 24, 2012 Started: Nov 30, 2007 Primary completion: Nov 30, 2008 Completion: Jan 31, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Poor enrollment

A PHASE2 clinical study on ST-Elevation Myocardial Infarction, this trial is terminated or withdrawn. The trial is conducted by Brigham and Women's Hospital and has accumulated 10 data snapshots since 2007. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Study Description(click to expand)

The primary objective of the IC-TITAN study is to demonstrate that an IC bolus of eptifibatide added to an upstream double-bolus and infusion regimen of eptifibatide administered intravenously and initiated early in the ER will result in significant additional clot resolution in vivo when compared with an IC injection of placebo (saline). The primary endpoint chosen to evaluate this hypothesis is the improvement in percent diameter stenosis of the culprit artery following the IC bolus administration of eptifibatide vs. IC placebo (saline) as assessed with quantitative coronary angiography (QCA).

The primary objective of the IC-TITAN study is to demonstrate that an IC bolus of eptifibatide added to an upstream double-bolus and infusion regimen of eptifibatide administered intravenously and initiated early in the ER will result in significant additional clot resolution in vivo when compared with an IC injection of placebo (saline). The primary endpoint chosen to evaluate this hypothesis is the improvement in percent diameter stenosis of the culprit artery following the IC bolus administration of eptifibatide vs. IC placebo (saline) as assessed with quantitative coronary angiography (QCA).

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 19 months · monthly snapshotTerminated~Jan 2026 – present · 3 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Present [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

▶ Show 5 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  3. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Brigham and Women's Hospital
  • Schering-Plough
Data source: Brigham and Women's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations